Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 5134602, 8 pages
https://doi.org/10.1155/2017/5134602
Research Article

The Use of Antidepressants, Anxiolytics, and Hypnotics in People with Type 2 Diabetes and Patterns Associated with Use: The Hoorn Diabetes Care System Cohort

1EMGO+ Institute for Health and Care Research, VU Medical Center, Amsterdam, Netherlands
2Department of Clinical Pharmacology and Pharmacy, VU Medical Center, Amsterdam, Netherlands
3Department of Epidemiology and Biostatistics, VU Medical Center, Amsterdam, Netherlands
4Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands
5Department of General Practice and Elderly Care Medicine, VU Medical Center, Amsterdam, Netherlands
6Department of Psychiatry, VU Medical Center, Amsterdam, Netherlands

Correspondence should be addressed to R. Mast; ln.cmuv@tsam.m

Received 21 August 2016; Accepted 27 December 2016; Published 23 January 2017

Academic Editor: Jessica J. Jalbert

Copyright © 2017 R. Mast et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Ali, M. A. Stone, J. L. Peters, M. J. Davies, and K. Khunti, “The prevalence of co-morbid depression in adults with Type-2 diabetes: a systematic review and meta-analysis,” Diabetic Medicine, vol. 23, no. 11, pp. 1165–1173, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Mezuk, W. W. Eaton, S. Albrecht, and S. H. Golden, “Depression and type 2 diabetes over the lifespan: a meta-analysis,” Diabetes Care, vol. 31, no. 12, pp. 2383–2390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. M. J. Knol, J. W. R. Twisk, A. T. F. Beekman, R. J. Heine, F. J. Snoek, and F. Pouwer, “Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis,” Diabetologia, vol. 49, no. 5, pp. 837–845, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. A. E. Mesas, P. Guallar-Castillón, E. López-García et al., “Sleep quality and the metabolic syndrome: the role of sleep duration and lifestyle,” Diabetes/Metabolism Research and Reviews, vol. 30, no. 3, pp. 222–231, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Nouwen, K. Winkley, J. Twisk et al., “Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis,” Diabetologia, vol. 53, no. 12, pp. 2480–2486, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. E. M. Van Weel-Baumgarten, M. G. Van Gelderen, H. G. L. M. Grundmeijer et al., “NHG Standaard Depressie M44,” Huisarts en Wetenschap, vol. 55, no. 6, pp. 252–259, 2012. View at Google Scholar
  7. N. J. Wolf and D. R. Hopko, “Psychosocial and pharmacological interventions for depressed adults in primary care: a critical review,” Clinical Psychology Review, vol. 28, no. 1, pp. 131–161, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Verweij and M. Houben-Van Herten, Bevolkingstrends 2013: Depressiviteit en Antidepressiva in Nederland. Centraal Bureau voor Statistiek, Centraal Bureau voor Statistiek, 2013.
  9. D. F. Kripke, R. D. Langer, and L. E. Kline, “Hypnotics' association with mortality or cancer: A Matched Cohort Study,” BMJ Open, vol. 2, no. 1, Article ID e000850, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Olfson and S. C. Marcus, “National patterns in antidepressant medication treatment,” Archives of General Psychiatry, vol. 66, no. 8, pp. 848–856, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. C. M. Sonnenberg, E. J. M. Biennali, D. J. H. Deeg, H. C. Comijs, W. Van Tilburg, and A. T. F. Beekman, “Ten-year trends in benzodiazepine use in the Dutch population,” Social Psychiatry and Psychiatric Epidemiology, vol. 47, no. 2, pp. 293–301, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Huerta, V. Abbing-Karahagopian, G. Requena et al., “Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project,” Pharmacoepidemiology and Drug Safety, vol. 25, pp. 56–65, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Baumeister, N. Hutter, and J. Bengel, “Psychological and pharmacological interventions for depression in patients with diabetes mellitus: an abridged Cochrane review,” Diabetic Medicine, vol. 31, no. 7, pp. 773–786, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Roy and C. E. Lloyd, “Epidemiology of depression and diabetes: a systematic review,” Journal of Affective Disorders, vol. 142, pp. S8–S21, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Kivimäki, A. G. Tabák, D. A. Lawlor et al., “Antidepressant use before and after the diagnosis of type 2 diabetes,” Diabetes Care, vol. 33, no. 7, pp. 1471–1476, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. R. I. Holt, M. de Groot, and S. H. Golden, “Diabetes and depression,” Current Diabetes Reports, vol. 14, no. 6, article no. 491, 2014. View at Publisher · View at Google Scholar
  17. P. Demakakos, M. Marmot, and A. Steptoe, “Socioeconomic position and the incidence of type 2 diabetes: the ELSA study,” European Journal of Epidemiology, vol. 27, no. 5, pp. 367–378, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Hwang and C. Shon, “Relationship between socioeconomic status and type 2 diabetes: results from Korea National Health and Nutrition Examination Survey (KNHANES) 2010–2012,” BMJ Open, vol. 4, no. 8, Article ID e005710, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Zavrelova, T. Hoekstra, M. Alssema et al., “Progression and regression: distinct developmental patterns of diabetic retinopathy in patients with type 2 diabetes treated in the Diabetes Care System West-Friesland, the Netherlands,” Diabetes Care, vol. 34, no. 4, pp. 867–872, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. G. E. H. M. Rutten, W. J. C. De Grauw, G. Nijpels et al., NHG Standaard Diabetes Type 2, 2013.
  21. E. Piek, B. J. Kollen, K. Van Der Meer, B. W. J. H. Penninx, and W. A. Nolen, “Maintenance use of antidepressants in dutch general practice: non-guideline concordant,” PLOS ONE, vol. 9, no. 5, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Boyd, S. Van de Velde, M. Pivette et al., “Gender differences in psychotropic use across Europe: Results From A Large Cross-sectional, Population-based Study,” European Psychiatry, vol. 30, no. 6, pp. 778–788, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Kovess-Masfety, A. Boyd, S. van de Velde et al., “Are there gender differences in service use for mental disorders across countries in the european union? Results from the EU-world mental health survey,” Journal of Epidemiology and Community Health, vol. 68, no. 7, pp. 649–656, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Pouwer, A. T. F. Beekman, G. Nijpels et al., “Rates and risks for co-morbid depression in patients with Type 2 diabetes mellitus: results from a community-based study,” Diabetologia, vol. 46, no. 7, pp. 892–898, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. R. J. Anderson, K. E. Freedland, R. E. Clouse, and P. J. Lustman, “The prevalence of comorbid depression in adults with diabetes: a meta-analysis,” Diabetes Care, vol. 24, no. 6, pp. 1069–1078, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. M. D. Pawaskar, V. N. Joish, F. T. Camacho, R. S. Rasu, and R. Balkrishnan, “The influence of co-morbidities on prescribing pharmacotherapy for insomnia: evidence from US national outpatient data 1995–2004,” Journal of Medical Economics, vol. 11, no. 1, pp. 41–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Hermanns, B. Kulzer, M. Krichbaum, T. Kubiak, and T. Haak, “Affective and anxiety disorders in a German sample of diabetic patients: prevalence, comorbidity and risk factors,” Diabetic Medicine, vol. 22, no. 3, pp. 293–300, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Mast, A. P. D. Jansen, I. Walraven et al., “Time to insulin initiation and long-term effects of initiating insulin in people with type 2 diabetes mellitus: The Hoorn Diabetes Care System Cohort Study,” European Journal of Endocrinology, vol. 174, no. 5, pp. 563–571, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Fisher, M. M. Skaff, J. T. Mullan, P. Arean, R. Glasgow, and U. Masharani, “A longitudinal study of affective and anxiety disorders, depressive affect and diabetes distress in adults with type 2 diabetes,” Diabetic Medicine, vol. 25, no. 9, pp. 1096–1101, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Bot, F. Pouwer, P. De Jonge, C. J. Tack, P. H. L. M. Geelhoed-Duijvestijn, and F. J. Snoek, “Differential associations between depressive symptoms and glycaemic control in outpatients with diabetes,” Diabetic Medicine, vol. 30, no. 3, pp. e115–e122, 2013. View at Publisher · View at Google Scholar · View at Scopus